These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37406106)

  • 1. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
    Maron SB; Chatila W; Walch H; Chou JF; Ceglia N; Ptashkin R; Do RKG; Paroder V; Pandit-Taskar N; Lewis JS; Biachi De Castria T; Sabwa S; Socolow F; Feder L; Thomas J; Schulze I; Kim K; Elzein A; Bojilova V; Zatzman M; Bhanot U; Nagy RJ; Lee J; Simmons M; Segal M; Ku GY; Ilson DH; Capanu M; Hechtman JF; Merghoub T; Shah S; Schultz N; Solit DB; Janjigian YY
    Clin Cancer Res; 2023 Sep; 29(18):3633-3640. PubMed ID: 37406106
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
    Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
    Jacobs SA; Wang Y; Abraham J; Feng H; Montero AJ; Lipchik C; Finnigan M; Jankowitz RC; Salkeni MA; Maley SK; Puhalla SL; Piette F; Quinn K; Chang K; Nagy RJ; Allegra CJ; Vehec K; Wolmark N; Lucas PC; Srinivasan A; Pogue-Geile KL
    Breast Cancer Res; 2024 Apr; 26(1):69. PubMed ID: 38650031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
    Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
    Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
    Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
    Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
    BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
    Makiyama A; Sukawa Y; Kashiwada T; Kawada J; Hosokawa A; Horie Y; Tsuji A; Moriwaki T; Tanioka H; Shinozaki K; Uchino K; Yasui H; Tsukuda H; Nishikawa K; Ishida H; Yamanaka T; Yamazaki K; Hironaka S; Esaki T; Boku N; Hyodo I; Muro K
    J Clin Oncol; 2020 Jun; 38(17):1919-1927. PubMed ID: 32208960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
    Wang DS; Liu ZX; Lu YX; Bao H; Wu X; Zeng ZL; Liu Z; Zhao Q; He CY; Lu JH; Wang ZQ; Qiu MZ; Wang F; Wang FH; Li YH; Wang XN; Xie D; Jia WH; Shao YW; Xu RH
    Gut; 2019 Jul; 68(7):1152-1161. PubMed ID: 30269082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma.
    Singh H; Lowder KE; Kapner K; Kelly RJ; Zheng H; McCleary NJ; Abrams TA; Chan JA; Regan EM; Klempner SJ; Hannigan AM; Remland J; Brais LK; Andrews E; Yurgelun M; Cleary JM; Rubinson DA; Ritterhouse LL; Maron G; Aguirre AJ; Meyerhardt JA; Gardecki E; Lennerz JK; Wolpin BM; Enzinger PC
    Nat Commun; 2024 Aug; 15(1):6833. PubMed ID: 39122726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
    Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
    Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer.
    Wang Y; Zhao C; Chang L; Jia R; Liu R; Zhang Y; Gao X; Li J; Chen R; Xia X; Bulbul A; Husain H; Guan Y; Yi X; Xu J
    EBioMedicine; 2019 May; 43():261-269. PubMed ID: 31031019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
    Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Cheng K; Song C; Wu H; Eng-Wong J; Kim K; Kang YK
    Lancet Oncol; 2018 Oct; 19(10):1372-1384. PubMed ID: 30217672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using
    Lumish MA; Maron SB; Paroder V; Chou JF; Capanu M; Philemond S; O'Donoghue JA; Schöder H; Lewis JS; Lyashchenko SK; Pandit-Taskar N; Janjigian YY
    J Nucl Med; 2023 May; 64(5):724-730. PubMed ID: 36418168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
    Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
    Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis.
    Hyung J; Lee JY; Kim JE; Yoon S; Yoo C; Hong YS; Jeong JH; Kim TW; Jeon S; Jun HR; Jung CK; Jang JP; Kim J; Chun SM; Ahn JH
    ESMO Open; 2023 Jun; 8(3):101583. PubMed ID: 37327700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
    Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
    Van Cutsem E; di Bartolomeo M; Smyth E; Chau I; Park H; Siena S; Lonardi S; Wainberg ZA; Ajani J; Chao J; Janjigian Y; Qin A; Singh J; Barlaskar F; Kawaguchi Y; Ku G
    Lancet Oncol; 2023 Jul; 24(7):744-756. PubMed ID: 37329891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
    Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.